Author details

Full Name

Peter M Haverty

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
32584896	Super-enhancer acquisition drives oncogene expression in triple negative breast cancer.	PLoS One	2020
30683138	Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens.		2019
31745090	Transposable element expression in tumors is associated with immune infiltration and increased antigenicity.	Nat Commun	2019
29370292	Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.	PLoS ONE	2018
30110629	Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.	Cell Rep	2018
29872725	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.	npj Precision Oncology	2018
30463956	Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration.	Proc Natl Acad Sci U S A	2018
28982154	Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.	PLoS ONE	2017
28819026	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.	Cancer Research	2017
27618686	Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis.	Cell Metab	2016
27193678	Reproducible pharmacogenomic profiling of cancer cell line panels.	Nature	2016
26711467	Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.	Molecular and Cellular Proteomics	2016
25759019	Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.	Cancer Cell	2015
25714623	Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system.	PLoS ONE	2015
25401301	Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.	Nat Genet	2015
25485619	A comprehensive transcriptional portrait of human cancer cell lines.	Nat Biotechnol	2015
25902869	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.	Breast Cancer Res	2015
25862760	An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.	Clinical Cancer Research	2015
25074413	PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.	J Pathol	2014
25315065	MBASED: allele-specific expression detection in cancer tissues and cell lines.	Genome Biol	2014
24297535	Integrative analysis of two cell lines derived from a non-small-lung cancer patient--a panomics approach.	Pac Symp Biocomput	2014
24807215	Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.	Nat Commun	2014
24755469	Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes.	Cancer Research	2014
25167216	Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.		2014
23188824	Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.	Journal of Biological Chemistry	2013
22370636	Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.	Oncogene	2013
23822816	Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers.	BMC Genomics	2013
24097869	Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.	Clinical Cancer Research	2013
23535073	P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.	J Natl Cancer Inst	2013
23033341	Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.	Genome Res	2012
22895193	Recurrent R-spondin fusions in colon cancer.	Nature	2012
22570710	Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.	PLoS ONE	2012
22267523	The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.	Genome Res	2012
22941189	Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.	Nat Genet	2012
22402123	ERK inhibition overcomes acquired resistance to MEK inhibitors.	Molecular Cancer Therapeutics	2012
23136191	Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.	Clinical Cancer Research	2012
21653999	p21-activated kinase 1: PAK'ed with potential.	Oncotarget	2011
22586611	PPM1H is a p27 phosphatase implicated in trastuzumab resistance.	Cancer Discov	2011
21482786	Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.	Proc Natl Acad Sci U S A	2011
21106550	Ascl2 and 11p15.5 amplification in colorectal cancer.	Gut	2011
20668451	Diverse somatic mutation patterns and pathway alterations in human cancers.	Nature	2010
20505728	The mutation spectrum revealed by paired genome sequences from a lung cancer patient.	Nature	2010
19372580	Genetic alterations and oncogenic pathways associated with breast cancer subtypes.	Molecular Cancer Research	2009
19509167	Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.	Clinical Cancer Research	2009
19419571	High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors.	BMC Med Genomics	2009
18335499	High-resolution genomic and expression analyses of copy number alterations in breast tumors.	Genes Chromosomes and Cancer	2008
17234753	Distinguishing cancer-associated missense mutations from common polymorphisms.	Cancer Res	2007
16046619	Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum.	Physiol Genomics	2005
15215383	CARRIE web service: automated transcriptional regulatory network inference and interactive analysis.	Nucleic Acids Res	2004
15256402	Limited agreement among three global gene expression methods highlights the requirement for non-global validation.	Bioinformatics	2004